On then selection of a tracer for PET imaging of HER2-expressing tumors: Direct comparison of a99mI-labeled affibody molecule and trastuzumab in a murine xenograft model

Journal of Nuclear Medicine

Volumn 50, Issue 3, 2009, Pages 417-425

  Orlova, Anna ^a,b   Wållberg, Helena ^a   Stone Elander, Sharon ^c   Tolmaehev, Vladimir ^a,b  

^a Affibody AB   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Affibody molecules; HER2; Imaging; Targeting; Xenografts

Indexed keywords

4 IODOBENZOIC ACID; 4 IODOBENZOIC ACID AFFIBODY Z HER2:342 I 124; 4 IODOBENZOIC ACID TRASTUZUMAB I 124; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IODINE 124; IODINE 125; SCAFFOLD PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG TARGETING; DRUG UPTAKE; FEMALE; ISOTOPE LABELING; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOACTIVITY; RADIOIODINATION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; HUMANS; IODINE RADIOISOTOPES; IODOBENZOATES; ISOTOPE LABELING; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 62449176798     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.057919     Document Type: Article

References (41)

1. Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors, Int J Radial Oncol Biol Phys. 2004;58:903-913.
2. Carlsson J. EGFR-family expression and implications for targeted radionuclide therapy. In: Stigbrand T, Carlsson J, Adams G. eds. Targeted Radionuclide Tumor Therapy: Biological Aspects. Dordrecht, The Netherlands: Springer; 2008:25-58.
3. Human Protein Atlas. Available at: http://www.proteinailas.org/. Accessed January 2, 2009.
4. Muss HB, Thor AD, Berry DA, et at. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994:330:1260-1266.
5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over- expresses HER2. N Engl J Med. 2001;344:783-792.
6. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.
7. Molina R, Barak V, van Dalen A, el al. Tumor markers in breast cancer: European Group on Tumor Markers recommendations. Tumour Biol. 2005:26:281-293.
8. Bartlell J, Mallon E, Cooke T. The clinical evaluation of HER-2 status: which test to use? J Pathol. 2003;199:411-417.
9. Zidan J, Dashkovsky I, Stayerman C, et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer. 2005;93:552-556.
10. Behr TM. Behe M, Wormann B. Trastuzumab and breast cancer. N Engl J Med. 2001:345:995-996.
11. Perik PJ, Lub-De Hooge MN, Gietema JA, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006;24:2276-2282.
12. Olafsen T. Tan GJ, Cheung CW, et al. Characterization of engineered anti- pl85HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel. 2004:17:315-323.
13. 111 -n-lrastuzumab (Herceplin) Fab fragments. Nucl Med Biol. 2005;32:51-58.
14. 111In labeled Herceptin. Nucl Med Biol. 2002;29: 599-606.
15. 86Brl(4 isothiocyanatobenzyl-ammonio)- bromo-decahydro- closo-dodecaborate (Bromo-DABI). Nucl Med Biol. 2004;31:205-211.
16. 89Zr- trastuzumab for clinical HER2 immunoPET imaging [abstract]. J Clin Oncol. 2007;25(suppl 18):S3508.
17. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol. 2004;22:701-706.
18. Olafsen T, Kenanova VE, Sundaresan G, et al. Optimizing radiolabeled engineered anti-pl85HER2 antibody fragments for in vivo imaging. Cancer Res. 2005;65:5907-5916.
19. Robinson VIK. Doss M. ShallerC, et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anli-HER2 diabody. Cancer Res. 2005:65:1471-1478.
20. Lundqvist H, Lubberink M, Totmachev V, et al. Positron emission tomography and radioimmunotargeting: general aspects. Acta Oncol. 1999;38:335-341.
21. Verel I, Visser GW, van Dongen GA. The promise of immuno-PET in radio- immunotherapy. J Nucl Med. 2005;46(suppl 1):164S-171S.
22. Van de Wiele C, Revets H, Menem H. Radioimmunoimaging: advances and prospects. Q J Nucl Med Mol Imaging. 2004;48:317-325.
23. Nygren PA. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J. 2008:275:2668-2676.
24. Tolmachev V, Orlova A, Nilsson FY, Feldwisch J, Wennborg A, Abrahmsen L. Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin Biol Then 2007;7:555-568.
25. Orlova A, Feldwisch J, Abrahmsen L, Totmachev V. Update: affibody molecules for molecular imaging and therapy for cancer. Cancer Biother Radiopharm. 2007;22:573-584.
26. Orlova A, Magnusson M, Eriksson T, et al. Tumor imaging using a picomolar affinity HER2 binding Affibody molecule. Cancer Res. 2006;66:4339-4348.
27. Baum RP, Orlova A, Tolmachev V, Feldwisch J. A novel molecular imaging agent for diagnosis of recurrent HER2 positive breast cancer: first time in human study using an indium-111- or gallium-68-labeled Affibody molecule [abstract]. Eur J Nucl Med Mol Imaging. 2006;33(suppl):S9l.
28. HER2:342-Affibody molecule: a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging. 2008;35:1008-1018.
29. 18F-labeled protein scaffold molecules. / Nucl Med. 2008;49:804-813.
30. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des. 2008:14:2999-3019.
31. Persson M, Sivaev 1, Winberg KJ, Gedda L, Malmstrom PU, Tolmachev V. In vitro evaluation of two polyhedral boron anion derivatives as linkers for attachment of radioiodine to anti-HER2 monoclonal antibody trastuzumab. Cancer Biother Radiopharm. 2007:22:585-596.
32. Steffen AC, Wikman M, Tolmachev V, et al. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biother Radiopharm. 2005;20:239-248.
33. Tolmachev V, Orlova A, Lundqvist H. Approaches to improve cellular retention of radiohalogen labels delivered by internalising tumor-targeting proteins and peptides. Curr Med Chem. 2003;10:2447-2460.
34. Koziorowski J, Henssen C, Weinreich R. A new convenient route to radioio- dinaled JV-succinimidyl 3- and 4-iodobenzoate, two reagents for iodination of proteins. Appl Radiat Isot. 1998;49:955-959.
35. Orlova A, Hoglund J, Lubberink M, et al. Comparative biodislribution of the radiohalogenated (Br. I and At) antibody A33: implication for in vivo dosimetry. Cancer Biother Radiopharm. 2002;17:385-396.
36. HER2:342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm. 2008;23:435-442.
37. Froidevaux S, Heppeler A, Eberle AN, et al. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4.7,10-telraazacyclododecane-1, 4,7.10-tetraacelie acid-somatostatin analogs for tumor diagnosis and interna] radiotherapy. Endocrinology. 2000:141:3304-3312.
38. Austin CD, De Maziere AM, Pisacane PI, el al. Endocylosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamyein. Mol Biol Cell 2004;15:5268-5282.
39. Verei I, Visser GW, Boerman OC, et al. Long-lived positron emitters zirconium- 89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm, 2003;18:655-661.
40. Orlova A, Tolmachev V, Pehrson R, et al. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res. 2007;67:2178-2186.
41. HER2:342-, an Affibody molecule-based tracer for detection of HER2-expression in malignant tumors. Bioconjug Chem, 2007;18:1956-1964.